Hot Features
Premium
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Athersys Inc | ATHX | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.1018 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.1018 | 0.1018 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 0.0938 - 1.14 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 0.1018 | USD |
Athersys Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 1.8M | 17.99M | - | 5.33M | -72.53M | -4.03 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Athersys News
| Date | Time | Source | News Article |
|---|---|---|---|
| 1/08/2024 | 06:31 | Edgar (US Regulatory) | Form 8-K - Current report |
| 12/22/2023 | 16:09 | Edgar (US Regulatory) | Form 8-K - Current report |
| 12/21/2023 | 10:37 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
| 11/16/2023 | 07:35 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
| 10/18/2023 | 07:00 | Edgar (US Regulatory) | Form 8-K - Current report |
| 10/16/2023 | 15:52 | Business Wire | Athersys Extends Near Term Liquidity with Proceeds from.. |
| 10/12/2023 | 08:28 | Edgar (US Regulatory) | Form 8-K - Current report |
| 10/11/2023 | 08:27 | Edgar (US Regulatory) | Form 8-K - Current report |
| 10/10/2023 | 07:30 | Business Wire | Athersys Reports Interim Analysis Results of MASTERS-2.. |
| 10/06/2023 | 16:34 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
| 10/06/2023 | 16:28 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
| 10/03/2023 | 15:41 | Edgar (US Regulatory) | Form 8-K - Current report |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ATHX Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 6 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Year | 0.88 | 1.14 | 0.0938 | 0.1678328 | 1,998,403 | -0.7782 | -88.43% |
| 3 Years | 43.25 | 45.50 | 0.0938 | 11.49 | 2,911,813 | -43.15 | -99.76% |
| 5 Years | 37.50 | 110.50 | 0.0938 | 28.30 | 2,573,489 | -37.40 | -99.73% |
Athersys Description
| Athersys Inc is a biotechnology company. It is focused on developing novel and proprietary therapies in the areas where there is an unmet medical need, particularly in the regenerative medicine area. The firm's main product is Multistem cell therapy. Its current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders and certain pulmonary conditions. Its revenue has been derived from corporate collaborations, license agreements, and government grants. |
